Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ALK status confers therapeutic sensitivity to Crizotinib in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
This statement is based on a regulatory approval from the European Medicines Agency:
XALKORI as monotherapy is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).